Tower Research Capital (TRC)’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22K Buy
19,127
+9,392
+96% +$12K ﹤0.01% 3416
2025
Q4
$10.6K Sell
9,735
-706
-7% -$789 ﹤0.01% 3736
2025
Q3
$10.5K Buy
10,441
+10,416
+41,664% +$11.4K ﹤0.01% 3976
2025
Q2
$29 Sell
25
-5,168
-100% -$6.67K ﹤0.01% 5207
2025
Q1
$7.74K Sell
5,193
-1,976
-28% -$2.37K ﹤0.01% 3935
2024
Q4
$5.87K Buy
7,169
+1,102
+18% +$972 ﹤0.01% 4232
2024
Q3
$4.95K Sell
6,067
-13,731
-69% -$11.2K ﹤0.01% 4364
2024
Q2
$16.2K Sell
19,798
-175
-0.9% -$148 ﹤0.01% 3870
2024
Q1
$16.2K Buy
19,973
+18,958
+1,868% +$24.6K ﹤0.01% 3201
2023
Q4
$1.43K Sell
1,015
-1,976
-66% -$2.6K ﹤0.01% 5382
2023
Q3
$3.5K Buy
2,991
+2,964
+10,978% +$4.3K ﹤0.01% 4996
2023
Q2
$38 Sell
27
-3,066
-99% -$4.62K ﹤0.01% 5887
2023
Q1
$4K Buy
3,093
+532
+21% +$737 ﹤0.01% 5082
2022
Q4
$3K Sell
2,561
-4,721
-65% -$8.49K ﹤0.01% 5207
2022
Q3
$11K Buy
+7,282
New +$18.1K ﹤0.01% 4451
2022
Q2
Sell
-3,548
Closed -$12K 6338
2022
Q1
$12K Buy
3,548
+2,467
+228% +$9.02K ﹤0.01% 4073
2021
Q4
$6K Buy
+1,081
New +$8.77K ﹤0.01% 5039

Other funds holding LUCD

Tower Research Capital (TRC)'s LUCD Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Lucid Diagnostics (LUCD) stake by 96% in Q1 2026, buying an estimated $12K and bringing the position to 19,127 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3416.

Tower Research Capital (TRC) first reported a position in LUCD in Q4 2021 and has held it in 17 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Tower Research Capital (TRC) held 19,127 shares of Lucid Diagnostics worth $22K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,392 Lucid Diagnostics shares in Q1 2026, an estimated $12K.
  • Lucid Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3416 holding.
  • Tower Research Capital (TRC) first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 17 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.